AUS
NZ
UK
CA
USA
IND
Highlights
- Hemogenyx Pharmaceuticals begins patient recruitment for Phase I trials of HG-CT-1, targeting relapsed/refractory acute myeloid leukemia (AML).
- The trial aims to evaluate HG-CT-1's safety profile and its impact on survival rates, response duration, and progression-free survival.
- The therapy leverages cutting-edge CAR-T technology, potentially offering a new treatment option for a disease with poor survival outcomes.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) has achieved a significant milestone in its mission to combat relapsed/refractory (R/R) acute myeloid leukemia (AML) by opening its first clinical site for HG-CT-1, its lead CAR-T therapy. Patient recruitment for the Phase I dose-escalation trial has officially commenced.
Phase I Trial Objectives
The primary goal of the Phase I trial is to evaluate the safety profile of HG-CT-1 in adult patients with R/R AML. Additionally, the study will assess key secondary objectives that aim to measure the therapy’s clinical efficacy:
- AML-Specific Response: Evaluating HG-CT-1's ability to elicit positive responses based on established AML response criteria.
- Overall Survival (OS): Monitoring survival rates of participants.
- Progression-Free Survival (PFS): Tracking the time patients remain free from disease progression.
- Duration of Response (DoR): Measuring the longevity of clinical responses achieved during the trial.
These metrics are vital in determining the potential of HG-CT-1 to improve outcomes for patients with R/R AML, a group with limited treatment options and poor prognoses.
Significance of HG-CT-1 for AML Treatment
AML is the most prevalent form of acute leukemia in adults, characterized by a five-year survival rate of less than 30%. Current standard-of-care treatments rely on chemotherapy, which is often toxic and has limited efficacy in advanced cases. Hemogenyx Pharmaceuticals' HG-CT-1, based on innovative CAR-T technology, offers a promising alternative.
CAR-T Therapy Explained
CAR-T therapy is a groundbreaking approach that uses a patient's own T-cells, genetically engineered to recognize and attack cancer cells. The process involves isolating the patient's T-cells, modifying them in a laboratory to express a chimeric antigen receptor (CAR) that targets cancer, amplifying the modified cells, and reintroducing them into the patient. This precise and personalized treatment method has already demonstrated transformative results in certain cancers, and HG-CT-1 aims to bring similar benefits to AML patients.
Partnering with a Prestigious Cancer Institution
The Phase I trial is being conducted at one of the world’s leading cancer research institutions, a testament to the scientific rigor and clinical promise of HG-CT-1.
Future Impact
The successful development of HG-CT-1 could revolutionize AML treatment, shifting the paradigm from traditional chemotherapy to a more targeted and potentially less toxic therapeutic option.
